Skip to content

US · AHCO · MEDICAL - DEVICES

AdaptHealth Corp. (AHCO) intrinsic value and stock valuation

$7.20as of 2026-11-21 · Mkt cap 774.15M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AdaptHealth Corp. DCF and intrinsic value

InvestorsCraft values AHCO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AHCO’s statements →

AdaptHealth Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Conshohocken, PA 19428 adapthealth.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$3.24B+25.2% 5y CAGRd
20162025
Net income
-$-70.79M
20162025
Free cash flow
$219.4M+7.1% 5y CAGRd
20162025
Total equity
$1.53B+40.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$3.24B$3.26B$3.2B$2.97B$2.45B
Operating income$186.3M$263.7M-$-598.4M$190.4M$225.6M
Net income-$-70.79M$90.4M-$-678.89M$69.3M$156.2M
EPSd-$-523.79K$667.2K-$-5.05M$498.7K$1.17M
Operating cash flow$601.8M$541.8M$480.7M$373.9M$275.7M
Capital expenditure-$-382.39M-$-306.06M-$-337.46M-$-391.42M-$-203.31M
Free cash flow$219.4M$235.8M$143.2M-$-17.56M$72.4M
Total assets$4.32B$4.49B$4.51B$5.22B$5.25B
Total debt$1.9B$2.13B$2.29B$2.33B$2.37B
Net debt$1.8B$2.02B$2.22B$2.28B$2.22B
Total equity$1.53B$1.58B$1.47B$2.16B$2.07B
Cash and short-term investments$106.1M$109.8M$77.1M$46.3M$149.6M
Income statement
20252024202320222021
Revenue$3.24B$3.26B$3.2B$2.97B$2.45B
Cost of revenue$2.68B$2.58B$2.52B$2.55B$2.01B
Gross profit$568.6M$681.1M$681.8M$417.4M$445.6M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$382.3M$359.2M$190.1M$162.1M$167.5M
Other expenses$0.00$58.1M$1.09B$64.9M$52.5M
Operating expenses$382.3M$417.4M$1.28B$227M$220M
Cost and expenses$3.06B$3B$3.8B$2.78B$2.23B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$105.8M$126.7M$130.3M$109.4M$95.2M
Depreciation and amortization$413M$365.3M$420.6M$423.4M$258.1M
Ebitda$503.6M$628M-$-171.09M$630.8M$544.2M
Operating income$186.3M$263.7M-$-598.4M$190.4M$225.6M
Total other income/expenses, net-$-201.42M-$-127.71M-$-125.38M-$-92.51M-$-34.65M
Income before tax-$-15.15M$136M-$-723.78M$97.9M$191M
Income tax expense$50.9M$41.2M-$-49M$24.8M$32.8M
Net income-$-70.79M$90.4M-$-678.89M$69.3M$156.2M
Weighted average shares outstanding$135.2M$133.8M$134.2M$134.2M$126.3M
Weighted average diluted shares outstanding$135.2M$135.5M$134.4M$139M$133M
Balance sheet
20252024202320222021
Cash and short-term investments$106.1M$109.8M$77.1M$46.3M$149.6M
Net receivables$370.9M$408M$388.9M$359.2M$359.9M
Inventory$151.3M$139.8M$113.6M$127.8M$123.1M
Total current assets$728.9M$755.8M$649M$585.3M$670.1M
Property, plant and equipment, net$674.2M$618.4M$637.5M$622M$546.3M
Goodwill and intangible assets$2.63B$2.78B$2.86B$3.71B$3.71B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.59B$3.73B$3.86B$4.63B$4.58B
Total assets$4.32B$4.49B$4.51B$5.22B$5.25B
Accounts payable$352.4M$284.6M$211.5M$222.5M$248M
Short-term debt$68.7M$60.5M$91.8M$67.2M$66.9M
Deferred revenue$59.8M$34.9M$38.6M$31.6M$31.4M
Total current liabilities$712.4M$567M$537M$456.2M$499.8M
Long-term debt$1.83B$2.07B$2.2B$2.26B$2.3B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.08B$2.34B$2.5B$2.61B$2.68B
Capital lease obligations$166.5M$149.2M$146.7M$140.6M$167M
Total liabilities$2.79B$2.91B$3.04B$3.06B$3.18B
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-632.97M-$-562.18M-$-652.6M$26.3M-$-43.02M
Accumulated other comprehensive income (loss)$80K$2.25M$4.36M$8.69M-$-2.35M
Total equity$1.53B$1.58B$1.47B$2.16B$2.07B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.9B$2.13B$2.29B$2.33B$2.37B
Net debt$1.8B$2.02B$2.22B$2.28B$2.22B
Cash flow statement
20252024202320222021
Net income-$-66.04M$94.8M-$-678.89M$73.1M$158.2M
Depreciation and amortization$381.9M$365.3M$420.6M$351.2M$258.1M
Stock-based compensation$21.9M$14.9M$22.5M$22.4M$25.3M
Change in working capital$66.6M-$-26.06M-$-25.11M-$-108M-$-153.31M
Accounts receivable$31M-$-26.22M-$-28.86M-$-210K-$-29.69M
Inventory-$-11.49M-$-28.07M$15.5M-$-6.3M-$-14.92M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$601.8M$541.8M$480.7M$373.9M$275.7M
Investments in property, plant and equipment-$-382.39M-$-306.06M-$-337.46M-$-391.42M-$-203.31M
Acquisitions, net-$-42.38M-$-9.54M-$-19.69M-$-19.02M-$-1.62B
Net cash used for investing activities-$-303.19M-$-310.27M-$-357.28M-$-411.17M-$-1.82B
Common stock issued$1.21M$0.00$0.00$0.00$278.9M
Common stock repurchased$0.00$0.00-$-29.27M-$-13.99M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-302.19M-$-198.95M-$-92.53M-$-66.05M$1.6B
Net change in cash-$-3.61M$32.6M$30.9M-$-103.36M$49.7M
Cash at end of period$106.1M$109.8M$77.1M$46.3M$149.6M
Operating cash flow$601.8M$541.8M$480.7M$373.9M$275.7M
Capital expenditure-$-382.39M-$-306.06M-$-337.46M-$-391.42M-$-203.31M
Free cash flow$219.4M$235.8M$143.2M-$-17.56M$72.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AdaptHealth Corp.

        AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea. It also furnishes essential medical devices and provisions for diabetes treatment, such as continuous glucose monitors and insulin pumps. AdaptHealth supplies HME to patients transitioning from acute care settings, offers in-home oxygen and chronic therapy services, and caters to chronically ill patients with specialized equipment and supplies for wound care, urological, incontinence, ostomy, and nutritional needs. These services are accessible to beneficiaries of Medicare, Medicaid, and various commercial insurance payors. AdaptHealth Corp. is primarily based in Plymouth Meeting, Pennsylvania.

        CEO
        Suzanne Foster
        Employees
        10.9K
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of AdaptHealth Corp. (AHCO)?

        AdaptHealth Corp. (AHCO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AHCO undervalued?

        AHCO trades at a price of $7.20 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.